anandamide (aea) plasma concentrations (Biotrial Inc)
90
Structured Review
Biotrial Inc
anandamide (aea) plasma concentrations
Anandamide (Aea) Plasma Concentrations, supplied by Biotrial Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anandamide+(aea)+plasma+concentrations/anandamide++aea++plasma+concentrations/pm28387940-102-50-47
Average 90 stars, based on 1 article reviews
Anandamide (Aea) Plasma Concentrations, supplied by Biotrial Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anandamide+(aea)+plasma+concentrations/anandamide++aea++plasma+concentrations/pm28387940-102-50-47
Average 90 stars, based on 1 article reviews
anandamide (aea) plasma concentrations - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Inhibition:Article Title: The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials. Article Snippet: BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.. The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multipleascending-dose phase (MAD).. Prospective determination of the starting dose and maximal escalated dose was consistent with the usual clinical pharmacology principles for extrapolation of preclinical toxicology data to human equivalent doses.After only 5–6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms. In Vitro:Article Title: The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials. Article Snippet: BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.. The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multipleascending-dose phase (MAD).. Prospective determination of the starting dose and maximal escalated dose was consistent with the usual clinical pharmacology principles for extrapolation of preclinical toxicology data to human equivalent doses.After only 5–6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms. In Vivo:Article Title: The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials. Article Snippet: BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.. The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multipleascending-dose phase (MAD).. Prospective determination of the starting dose and maximal escalated dose was consistent with the usual clinical pharmacology principles for extrapolation of preclinical toxicology data to human equivalent doses.After only 5–6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms. Clinical Proteomics:Article Title: The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials. Article Snippet: BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.. The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multipleascending-dose phase (MAD).. Prospective determination of the starting dose and maximal escalated dose was consistent with the usual clinical pharmacology principles for extrapolation of preclinical toxicology data to human equivalent doses.After only 5–6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms. |